Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Goldman Sachs Reiterates Neutral Rating on Viatris (VTRS)
July 18, 2025 9:48 AM EDTGoldman Sachs analyst Matt Dellatorre reiterated a Neutral rating and $10.00 price target on Viatris (NASDAQ: VTRS).
The analyst comments "VTRS announced that the Ph3 study evaluating MR-139 (pimecrolimus 0.3% ophthalmic ointment) in patients with blepharitis, did not meet its primary endpoint of... More
